Pipeline

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market.

Javelin’s development program is designed to support global registration, although special emphasis is placed upon U.S. and European filings for drug approval and product registration. The three product candidates, their indications, and their stages of clinical development in the United States and Europe are:

Product candidate		Indication			Development stage
Dyloject™		U.S.	Post operative Pain		Phase III
(injectable diclofenac)		Europe	Post operative Pain, Anti-inflammatory		MHRA Approval - October 31, 2007
Rylomine™		U.S.	Acute pain		Phase III
(intranasal morphine)		Europe	Acute pain		Phase II
PMI-150		U.S.	Acute moderate-to-severe pain		Phase III
(intranasal ketamine)		Europe	Acute moderate-to-severe pain		Phase III

CONTACT US   JOIN US   SITE MAP
© 2005-2006 Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.